Purpose of this Study
We are doing this study to find out if an experimental drug called IMM-1-104 (the study drug) is a safe and effective option for patients with melanoma, pancreatic cancer, or lung cancer. We also want to find out what dose of the study drug works best.
Who Can Participate?
Eligibility
Adults ages 18+ who:
- Are diagnosed with one of the following cancers: melanoma, pancreatic cancer, or lung cancer
- Have documented RAS-mutated advanced or metastatic solid tumor(s)
What is Involved?
Description
If you choose to join the study, you will go through a screening period to find out if you are eligible. During this period, you will:
- Have a physical exam
- Have a heart scan (ECG)
- Have blood draws
- Have a tumor
- Have imaging (CT scan or MRI)
Study Details
Full Title
A Phase 1/2a, Open-Label, Multicenter, Nonrandomized, Safety and Anti-tumor Activity Study of IMM-1-104, a Novel Oral Dual MEK1/2 Inhibitor in Participants with Previously Treated RAS-Mutated Advanced or Metastatic Solid Tumors
Principal Investigator
Jeffrey
Clarke
Protocol Number
PRO00114623
NCT ID
NCT05585320
Phase
I/II
Enrollment Status
Open to Enrollment